The long-term follow-up of the Hancock Modified Orifice porcine bioprosthetic valve

J Card Surg. 1991 Dec;6(4 Suppl):557-61. doi: 10.1111/jocs.1991.6.4s.557.

Abstract

The Hancock Modified Orifice valve is a specially fabricated, trileaflet porcine valve, which has been in clinical use at the Brigham and Women's Hospital since 1976. Three hundred seventy-nine aortic valve replacements with this device were implanted from 1976 to 1985; 305 were isolated aortic valve replacements and 74 were in association with a mitral valve bioprosthesis. The 305 patients undergoing isolated aortic valve replacement, a Food and Drug Administration patient group, are the subject of this article. The mean valve size was 22.5 mm, with 115 21-mm valves used. The mean functional preoperative class was 3.2; 99 of 305 patients (32.5%) underwent concomitant coronary artery bypass grafting. There were six operative deaths (2%). Patients were followed from 6-14 years (mean 7.4 years), and analysis was completed in early 1991. The 10-year actuarial calculation of survival freedom from reoperation, thromboembolism, structural valve degeneration, perivalvular leak, infectious valve degeneration, and total morbidity and mortality are presented.

MeSH terms

  • Actuarial Analysis
  • Adolescent
  • Adult
  • Aged
  • Aortic Valve
  • Bioprosthesis*
  • Female
  • Follow-Up Studies
  • Heart Valve Prosthesis / adverse effects
  • Heart Valve Prosthesis / mortality*
  • Humans
  • Male
  • Middle Aged
  • Mitral Valve
  • Survival Rate
  • Time Factors